Constellation Pharmaceuticals, Inc.

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating Constellation (Nasdaq: CNST) for possible breaches of fiduciary duty and other violations of law in its transaction with MorphoSys.

Ademi LLP alleges Constellation’s financial outlook is excellent and yet Constellation shareholders will receive only $34 for each share of Constellation common stock. The merger agreement unreasonably limits competing bids for Constellation by prohibiting solicitation of further bids, and imposing a termination penalty if Constellation accepts a superior bid. Constellation insiders will receive millions of dollars as part of change of control arrangements. We are investigating the conduct of Constellation’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Constellation.